The financials
Royalty Pharma plc by the numbers
Royalty Pharma plc (RPRX) reported revenue of $674M in Q2 2026 (quarter ended June 30, 2026), up 16% from the same quarter a year earlier. That came with net income of $18M (2.7% of revenue). For the full year FY2025, revenue was $2.38B (+5.1% year on year) and net income $771M. Its largest product in 2026-Q1 was Financial Royalty Assets at $595M, 94% of the disclosed total, just ahead of Royalty Income Other at 5.6%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $674M | $579M | +16% |
| Operating income | $133M | $210M | −37% |
| Net income | $18M | $32M | −44% |
| Diluted EPS | $0.04 | $0.07 | −43% |
| Product | Revenue | Share |
|---|---|---|
| Financial Royalty Assets | $595M | 94% |
| Royalty Income Other | $36M | 5.6% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $630.6M (+3.5%)
Royalty Income Other grew +24% year on yearFinancial Royalty Assets +10% year on year
Segment Latestquarter on quarteryear on year
- Financial Royalty Assets$595.0M$595.0MQoQ +2.8%year on year +10%+2.8%+10%
- Royalty Income Other$35.6M$35.6MQoQ +17%year on year +24%+17%+24%